PMOS (Polycystic Metabolic Ovarian Syndrome): What Has Changed with the New 2026 Definition
In 2026, leading international scientific societies—including the European Society of Endocrinology (ESE) and the Androgen Excess and PCOS Society—adopted updated terminology to describe the syndrome: from PCOS (Polycystic Ovary Syndrome) to PMOS (Polycystic Metabolic Ovarian Syndrome). This change in nomenclature reflects a profoundly renewed understanding of the condition.
Why the Change from PCOS to PMOS
The old term "polycystic ovary syndrome" carried three fundamental problems:
- It emphasized the ovaries as the primary site of the problem, while research over the past 15 years has clarified that insulin resistance and metabolic dysfunction are the primary cause, not a consequence
- It excluded the metabolic context: many women sought treatment only for acne and irregular cycles, without their doctor addressing the risk of type 2 diabetes, cardiovascular disease, and metabolic syndrome
- "Polycystic" was misleading: ovarian cysts on ultrasound are present in only 2/3 of PCOS cases; many women with the syndrome do not have them—and many healthy women do
The new definition PMOS—Polycystic Metabolic Ovarian Syndrome—shifts the focus:
- It recognizes metabolic dysfunction as a central, not secondary, element
- It explicitly includes insulin resistance as a key diagnostic criterion
- It encourages an integrated therapeutic approach that includes glycemic control and body composition, not just cycle regularization
The New PMOS 2026 Diagnostic Criteria
The ESE/AE-PCOS 2026 task force proposed a 3-axis system:
| Axis | Criteria | Assessment method |
|---|---|---|
| Axis 1: Ovarian | Oligoanovulation (<8 cycles/year) and/or polycystic ovarian morphology on high-resolution ultrasound | Transvaginal ultrasound with ≥8 MHz probe |
| Axis 2: Androgenic | Clinical hyperandrogenism (acne, hirsutism, alopecia) or biochemical (elevated free testosterone, increased free androgen index) | Hormone test (total/free testosterone, SHBG, DHEA-S) |
| Axis 3: Metabolic (new) | Insulin resistance (HOMA-IR ≥2.5 or fasting insulin ≥12 µU/mL) and/or metabolic syndrome (≥3 IDF criteria) | Fasting insulin + HOMA-IR; lipid panel; waist circumference |
PMOS is diagnosed with ≥2 positive axes. Axis 3 (metabolic) can replace Axis 1 as the second criterion—recognizing that many women with significant metabolic dysfunction have normal or near-normal cycles.
What Changes in Clinical Practice
For diagnosis
- Fasting insulin and HOMA-IR become routine tests in PMOS workup—no longer requested only in cases of "suspected insulin resistance"
- OGTT with insulin curve (not just glucose curve) is recommended for women with regular cycles but other criteria present
- Body composition (BIA scale or DEXA) is included in recommendations as a tool for visceral fat assessment
For treatment
- Metformin becomes first-line treatment not only for "obese" women with PMOS but for all those with elevated HOMA-IR, regardless of weight
- Home glycemic monitoring is included in recommendations for women with PMOS who are pre-diabetic or have borderline fasting glucose
- Therapeutic goals now explicitly include: HOMA-IR <2.5, fasting glucose <100 mg/dL, triglycerides <150 mg/dL—not just cycle regularization
For long-term monitoring
- Annual glucose and HbA1c screening—no longer every 2–3 years as in old PCOS guidelines
- Semi-annual blood pressure check
- Annual lipid panel
- Liver ultrasound every 2 years (PMOS is associated with fatty liver in 30–40% of cases)
PMOS and Home Monitoring
The new PMOS classification emphasizes the importance of proactive home monitoring. Two tools become central:
- Glucometer: women with PMOS can have an elevated postprandial glucose response even with normal fasting glucose. Measuring 1h after meals allows early identification of insulin resistance and personalized diet optimization. The G1 Pro—with Bluetooth and app—is the ideal tool for building a continuous glycemic diary to share with your doctor.
- Body composition scale: visceral fat—now an explicit metabolic criterion in PMOS—is better monitored with BIA than with waist circumference alone. The Brio 1 Pro measures visceral fat (scale 1–59) and full body composition with each weighing.
Frequently Asked Questions
I already have a PCOS diagnosis—do I need to be re-diagnosed with PMOS?
It is not necessary to formally re-diagnose—PMOS is a terminological evolution of the same condition. What matters in practice is that your doctor also assesses the metabolic component (insulin, HOMA-IR, lipid panel) if it has never been done.
Does PMOS also affect lean women?
Yes. Metabolic dysfunction in PMOS is not synonymous with being overweight: many normal-weight women with PMOS have elevated HOMA-IR and hyperinsulinemia. The new classification explicitly recognizes this aspect—which old guidelines often underestimated.